Based on this evidence and considering that the inhibition of PI3K/AKT pathway is associated with adverse events such as hyperglycemia and hyperinsulinemia [11], great interest is focused on the identification of new and specific inhibitors of the three AKT isoforms in different types of cancer. This evidence concerns the gene AKT1 and Hyperinsulinemia.